Proteins IGFBP-4 , Human
- Known as:
- Proteins IGFBP-4 , Human
- Catalog number:
- C347
- Product Quantity:
- 10μg
- Category:
- -
- Supplier:
- Novoprotein
- Gene target:
- Proteins IGFBP-4 Human
Related genes to: Proteins IGFBP-4 , Human
- Gene:
- IGFBP4 NIH gene
- Name:
- insulin like growth factor binding protein 4
- Previous symbol:
- -
- Synonyms:
- IBP4, BP-4, HT29-IGFBP, IGFBP-4
- Chromosome:
- 17q21.2
- Locus Type:
- gene with protein product
- Date approved:
- 1991-07-09
- Date modifiied:
- 2015-11-12
Related products to: Proteins IGFBP-4 , Human
Related articles to: Proteins IGFBP-4 , Human
- Pathological cardiac hypertrophy, a major contributor to heart failure, is characterized by an abnormal increase in the size of atria and ventricles. In the context of ventricular hypertrophy, the right ventricle (RV) exhibits less resistance to hypertrophy than the left one (LV). Insulin-like growth factors (IGF-1 and IGF-2) are critical for cell growth and provide cardioprotective effects. Pregnancy-associated plasma protein-A (PAPP-A) is a protease that cleaves insulin-like growth factor-binding protein-4 (IGFBP-4) and enhances IGF bioavailability. This study investigated PAPP-A-mediated IGFBP-4 proteolysis-one possible mechanism of IGF release regulation in rat models of right ventricular (RVH) and left ventricular (LVH) hypertrophy. RVH was induced with monocrotaline, and LVH via renovascular hypertension (1 Kidney 1 Clip (1K1C) model). Systolic blood pressure was measured using tail-cuff plethysmography. Heart morphometry was used to assess the mass of cardiac chambers. Cardiomyocyte purity was confirmed via troponin I immunocytochemistry. Plasma natriuretic type-B peptide (BNP) and C-terminal IGFBP-4 (CT-IGFBP-4) concentrations were quantified by fluoroimmunoassay. RVH and LVH were successfully modelled, with 1.6-fold and 1.3-fold increases in RV ( < 0.0001) and LV masses ( < 0.05), respectively. Plasma BNP was 2-3 times higher in LVH versus control rats. Hypertrophied cardiomyocytes secreted significantly more BNP than controls, showing 3.3-fold and 4.1-fold increases in LVH and RVH, respectively. PAPP-A-mediated IGFBP-4 proteolysis was 4-fold higher in RVH compared to control, but unaffected in LVH. These findings suggest that PAPP-A-specific elevation of IGFBP-4 proteolysis occurs predominantly in RVH, suggesting a differential IGF bioavailability in both ventricles and highlighting PAPP-A as a potential target to increase RVH resistance to hypertrophy. - Source: PubMed
Publication date: 2026/03/18
Artemieva Marina MMakeeva Arina VAdasheva Daria AShein Viacheslav EKatrukha Alexey GPostnikov Alexander BMedvedeva Natalia ASerebryanaya Daria V - Gastric cancer is one of the leading causes of cancer-related deaths worldwide, and due to its late-stage diagnosis, the prognosis is poor. Therefore, researching biomarkers that can be used in early diagnosis and prognostic processes is crucial. Insulin-like growth factor (IGF) signaling pathways play critical roles in cellular proliferation, apoptosis, differentiation, and tumor progression. This study investigated the biomarker potential of IGF-1, IGFBP-4, IGFBP-5, and PAPP-A in gastric cancer. Forty gastric cancer patients and forty healthy individuals were included, and protein levels in serum samples were measured using the ELISA method. The findings showed that IGF-1 levels were significantly decreased in the gastric cancer group, while IGFBP-4 levels were significantly increased. IGFBP-5 levels were also lower in gastric cancer patients. In contrast, PAPP-A levels did not differ significantly between the two groups. ROC analyses revealed that IGF-1, IGFBP-4, and IGFBP-5 have good discriminatory properties in the diagnosis of gastric cancer, while PAPP-A offers low diagnostic value. In conclusion, this study suggests that IGF pathway components, particularly IGF-1, IGFBP-4, and IGFBP-5, might be promising biomarker candidates for gastric cancer. - Source: PubMed
Publication date: 2025/11/10
Ceylaner BetulSahin FurkanYildiz AnilTastekin DidemGok Ali Fuat KaanBaykal Ahmet Tarik - Reproductive processes in mammals involve complex interactions between sex steroids and growth factor systems. Understanding these interactions in the uterus during different stages of the reproductive cycle is essential for elucidating the mechanisms of endometrial regulation. - Source: PubMed
Gossler Vanessa da Silva AlvesNunes Sarah GomesGarcia Santos Francislaine Anelizede Oliveira Santos AlineMattoso Miskulin Cardoso Ana PaulaPapa Paula de CarvalhoMarçal Natalia Caroline de Oliveirade Souza Lilian Francisco ArantesCastilho CaliêFloriano Rafael StuaniGiometti Ines Cristina - Insulin-like growth factor binding protein-4 (IGFBP-4) fragments are reported as emerging biomarkers for cardiovascular disease (CVD) risk assessment. To ensure data reliability and improve clinical application, the first automatic chemiluminescent immunoassay (CLIA) for NT-IGFBP-4 was developed and its distribution across CVDs was evaluated in this study. - Source: PubMed
Publication date: 2025/08/25
Cao ShuzhengWang JingLi LingWu YuYang JuanZhang LitaoShu XinWang HuiJing YishaZhang YiZhang Zhenlu - Pregnancy-associated plasma protein-A (PAPP-A) regulates bioavailability of insulin-like growth factor 1 (IGF1) in various tissues by proteolytic cleavage of a subset of IGF-binding proteins (IGFBPs). Pre-clinical studies have established a role of PAPP-A in atherosclerosis and proposed that targeting the proteolytic activity of PAPP-A has therapeutic value.This study aimed to investigate whether human atherosclerotic plaques contain proteolytically active PAPP-A, a prerequisite for further considering PAPP-A as a therapeutic target in patients. - Source: PubMed
Publication date: 2024/09/05
Gude Mette FaurholdtHjortebjerg RikkeBjerre MettePedersen Anne Kathrine NissenOxvig ClausRasmussen Lars MelholtFrystyk JanSteffensen Lasse